Rotterdam, The Netherlands
30 April - 4 May 2011


Novartis Oncology delivers innovative therapies that help change the way patients live with cancer and blood disorders. These include Glivec® (imatinib), Tasigna® (nilotinib), Afinitor® (everolimus), Zometa® (zoledronic acid), Femara® (letrozole), Sandostatin® LAR® (octreotide) and Exjade® (deferasirox). Novartis Oncology has a robust pipeline that utilizes recent discoveries in molecular genomics, rational drug design and state-of-the-art drug discovery technologies.